揭示PSMA5在胶质瘤进展和预后中的作用。

Unveiling the role of PSMA5 in glioma progression and prognosis.

作者信息

Liu Wei, Jia Bo, Wang Zan, Li Chengcai, Li Nanding, Tang Jie, Wang Jiwei

机构信息

Department of Neurosurgery, The First Hospital of Hebei Medical University, Shijiazhuang, China.

Department of Neurosurgery, Hebei Hospital of Xuanwu Hospital Capital Medical University, Shijiazhuang, China.

出版信息

Discov Oncol. 2024 Sep 6;15(1):414. doi: 10.1007/s12672-024-01296-3.

DOI:10.1007/s12672-024-01296-3

PMID:39240463

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11379840/

Abstract

Glioma is the most aggressive intracranial malignancy and is associated with poor survival rates and limited quality of life, impairing neuropsychological function and cognitive competence in survivors. The Proteasome Subunit Alpha Type-5 (PSMA5) is a multicatalytic proteinase complex that has been linked with tumor progression but is rarely reported in glioma. This study investigates the expression pattern, prognostic characteristics, and potential biological functions of PSMA5 in glioma. PSMA5 was significantly overexpressed in 28 types of cancer when compared to normal tissue. Furthermore, elevated levels of PSMA5 were observed in patients with wild-type isocitrate dehydrogenase 1 and exhibited a positive correlation with tumor grade. It was also found to be a standalone predictor of outcomes in glioma patients. Additionally, inhibiting PSMA5-induced cell cycle arrest may provide a therapeutic option for glioma.

摘要

神经胶质瘤是最具侵袭性的颅内恶性肿瘤，与生存率低和生活质量受限相关，会损害幸存者的神经心理功能和认知能力。蛋白酶体α5亚基（PSMA5）是一种多催化蛋白酶复合物，与肿瘤进展有关，但在神经胶质瘤中鲜有报道。本研究调查PSMA5在神经胶质瘤中的表达模式、预后特征及潜在生物学功能。与正常组织相比，PSMA5在28种癌症中显著过表达。此外，在异柠檬酸脱氢酶1野生型患者中观察到PSMA5水平升高，且与肿瘤分级呈正相关。还发现它是神经胶质瘤患者预后的独立预测指标。此外，抑制PSMA5诱导的细胞周期停滞可能为神经胶质瘤提供一种治疗选择。